Botulinum Toxin Injections to Treat Neurogenic Bladder — Sphincter Dysfunction in Pediatric Patients

  • Brigitte Schurch
  • Gilles Karsenty
  • Jacques Corcos


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bauer SB, Hallett M, Khoshbin S, et al. Predictive value of urodynamic evaluation in newborns with myelodysplasia. J Am Med Assoc 1984; 252:650–652.CrossRefGoogle Scholar
  2. 2.
    McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol 1981; 126:205–209.PubMedGoogle Scholar
  3. 3.
    Van Gool J. Neuropathic and non-neuropathic bladder-sphincter dysfunction in children. Pediatr Adoles Med 1994;5:178–182.Google Scholar
  4. 4.
    Baskin LS, Kogan BA, Benard F. Treatment of infants with neurogenic bladder dysfunction using anticholinergic drugs and intermittent catheterisation. Br J Urol 1990; 66:532–534.PubMedCrossRefGoogle Scholar
  5. 5.
    Joseph DB, Bauer SB, Colodny AH, et al. Clean, intermittent catheterization of infants with neurogenic bladder. Pediatrics 1989; 84:78–82.PubMedGoogle Scholar
  6. 6.
    Edelstein RA, Bauer SB, Kelly MD, et al. The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy. J Urol 1995; 154:1500–1504.PubMedCrossRefGoogle Scholar
  7. 7.
    Hernandez RD, Hurwitz RS, Foote JE, et al. Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele. J Urol 1994; 152(5Pt 1):1582–1585.PubMedGoogle Scholar
  8. 8.
    Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164(3 Pt 1):692–697.PubMedGoogle Scholar
  9. 9.
    Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45:510–515.PubMedCrossRefGoogle Scholar
  10. 10.
    Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174:196–200PubMedCrossRefGoogle Scholar
  11. 11.
    Mall V, Glocker FX, Frankenschmidt A, Gordjani N, Heinen F, Brandis M, Korinthenberg R. Treatment of neuropathic bladder using botulinum toxin A in a 1-year-old child with myelomeningocele. Pediatr Nephrol 2001; 16:1161–1162.PubMedCrossRefGoogle Scholar
  12. 12.
    Schulte-Baukloh H, Knispel HH, Michael T. Botulinum-A toxin in the treatment of neurogenic bladder in children. Pediatrics 2002; 110(2 Pt 1):420–421.PubMedCrossRefGoogle Scholar
  13. 13.
    Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH. Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 2003; 44:139–143PubMedCrossRefGoogle Scholar
  14. 14.
    Riccabona M, Koen M, Schindler M, et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004; 171(2 Pt 1):845–848.PubMedCrossRefGoogle Scholar
  15. 15.
    Corcos J, Al-Taweed W, Robichaud C. Botulinum toxin as an alternative treatment to bladder augmentation in children with neurogenic bladder due to myelomeningocele. J Urol 2004; 171:181Google Scholar
  16. 16.
    Drachman D. Botulinum toxin as a tool for research in the nervous system. In: Simspon L, editor. Neuropoisons: their pathophysiological actions. New York: Plenum Press; 1971. pp. 325–347.Google Scholar
  17. 17.
    Coffield J, Considine R, Simspon L. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. pp. 3–14.Google Scholar
  18. 18.
    Smith CP, Franks ME, McNeil BK, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003; 169:1896–1900.PubMedCrossRefGoogle Scholar
  19. 19.
    MacKenzie I, Burnstock G, Dolly JO. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 1982; 7:997–1006.PubMedCrossRefGoogle Scholar
  20. 20.
    Smith C, Fraser M, Bartho L, et al. Botulinum toxin A inhibits afferent nerve evoked bladder strip contractions. J Urol 2002;167:41.Google Scholar
  21. 21.
    Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990; 40:277–280.PubMedCrossRefGoogle Scholar
  22. 22.
    Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, Fowler CJ, Anand P: Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174:977–983.PubMedCrossRefGoogle Scholar
  23. 23.
    DeLaet K, Wyndaele JJ. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 2005; 43:397–399.CrossRefGoogle Scholar
  24. 24.
    Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med 1993; 86:493–494.PubMedGoogle Scholar
  25. 25.
    Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994; 9:31–39.PubMedCrossRefGoogle Scholar
  26. 26.
    Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 1993; 43:834–836.PubMedGoogle Scholar
  27. 27.
    Grosse J, Kramer G, Stöhrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47:653–659PubMedCrossRefGoogle Scholar
  28. 28.
    Haferkamp A, Schurch B, Reitz A, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type an in overactive neurogenic bladder. Eur Urol 2004; 46:784–791.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Brigitte Schurch
    • 1
  • Gilles Karsenty
    • 1
  • Jacques Corcos
    • 2
  1. 1.Department of Neuro-Urology Swiss Paraplegic CenterBalgrist University HospitalZurichSwitzerland
  2. 2.Shriners Hospital and McGill UniversityMontrealCanada

Personalised recommendations